Creative Biolabs is a world-leading innovative biotechnology company that has been at the forefront of aptamer research for decades. At Creative Biolabs, we specialize in custom bispecific aptamers development services tailored to your specific needs. Our vision is to provide reasonable solutions and one-stop services to help global customers make breakthroughs in the aptamers field.
Aptamers are single-stranded DNA or RNA sequences selected from oligonucleotide libraries by systemic evolution of ligands by exponential enrichment (SELEX) technology. Compared with antibodies, aptamers have multiple desirable characteristics, such as high specificity, high affinity, low immunogenicity and toxicity, ease of synthesis, and minor lot-to-lot variation. In recent years, aptamers have gradually emerged as the focus of research due to their unique properties. Aptamers can specifically bind to a variety of targets, such as bacteria, viruses, proteins, toxins, cancer cells, and tissues, making them crucial tools in diagnostics and therapeutics. Furthermore, aptamers also bind to non-coding RNAs, drugs, nanoparticles, and proteins for sensing, imaging, and targeted drug delivery purposes.
Similar to bispecific antibodies, two aptamers with different functions can be combined to form a new bispecific aptamer. Bispecific aptamers have been generated to interact with two independent targets simultaneously. For example, the chimerism of two aptamers yields bispecific aptamers capable of simultaneously binding two different cell surface receptors on cancer cells and lymphocytes. Recently, these bispecific aptamers have played an increasingly pivotal role in the diagnostic and therapeutic fields.
Fig.1 Design of bispecific aptamer. (Yu, 2022)
Cell surface receptors have gradually become attractive drug targets due to their close connection with the regulation of intracellular signal transduction. Bispecific aptamer-induced artificial protein pairings were developed to selectively modulate receptor function. Notably, paired proteins not only improve cell selectivity as cancer biomarkers but also inhibit target receptor function. This strategy provides a promising approach to designing molecular mediators that can modulate receptor function, thereby opening new prospects for developing novel therapeutics.
The excellent nuclease resistance of bispecific aptamers endows them with high structural integrity and robust binding capacity under physiological conditions. Thus, bispecific aptamers provide a general molecular recognition strategy to construct highly efficient bispecific protein aptamer assemblies on the cell membrane for functional protein delivery, which enables bispecific aptamers to act as attractive molecular linkers for the delivery of functional proteins.
Evidence suggests that bispecific aptamers contribute to enhancing clinical anticancer outcomes. Bispecific aptamers exert anticancer/anti-tumor effects by recruiting immune systems effector cells such as natural killer cells, dendritic cells, and effector T lymphocytes to target tumor cells. In addition, bispecific aptamers are also able to detect target cells and deliver drug molecules to specific cells, thereby effectively improving the efficacy of anticancer drugs under complex conditions.
Fig.2 Bispecific aptamers with antitumor immunity impacts. (Vandghanooni, 2018)
As a global biotechnology company, Creative Biolabs is dedicated to providing a broad range of high-quality products and services to researchers in need, including aptamer screening, analysis, and related conjugation services. Please contact us to tell us your needs, we will provide you with complete and innovative bispecific aptamer solutions and the highest quality products and services to help you solve the problems you encounter during your research.
References
1. Yu, S.; et al. Drug discovery of sclerostin inhibitors. Acta Pharmaceutica Sinica B. 2022.
2. Vandghanooni, S.; et al. Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective. Journal of molecular medicine. 2018, 96(9): 885-902.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRY
SERVICES
PRODUCTS
PLATFORMS
